Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
Clinical trial NCT06751901 · RECRUITING
Trial details
- NCT number
- NCT06751901
- Sponsor
- The First Affiliated Hospital of Nanchang University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-11
- Primary completion
- 2026-03-10
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.